NEW YORK (360Dx) — HalioDx today announced that Gencell Pharma will market and distribute the Immunoscore Colon assay in Colombia.

HalioDx's test predicts the risk of recurrence in patients with early-stage colon cancer and guides oncologists in decisions about therapies for stage II and III colon cancers. Combining tissue diagnostic and advanced image analysis technologies, Immunoscore Colon quantifies T-cells which have penetrated into the core of the colon core and its invasive margin.

Financial and other terms of the deal were not disclosed.